Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amini-Salehi Ehsan, Letafatkar Negin, Norouzi Naeim, Joukar Farahnaz, Habibi Arman, Javid Mona, Sattari Nazila, Khorasani Mehrdad, Farahmand Ali, Tavakoli Shervin, Masoumzadeh Behnaz, Abbaspour Elaheh, Karimzad Sahand, Ghadiri Amir, Maddineni Gautam, Khosousi Mohammad Javad, Faraji Niloofar, Keivanlou Mohammad-Hossein, Mahapatro Abinash, Gaskarei Mohamad Amin Khajavi, Okhovat Paria, Bahrampourian Ali, Aleali Maryam Sadat, Mirdamadi Arian, Eslami Narges, Javid Mohamadreza, Javaheri Naz, Pra Shrinidhi Vilas, Bakhsi Arash, Shafipour Mohammad, Vakilpour Azin, Ansar Malek Moein, Kanagala Sai Guatham, Hashemi Mohamad, Ghazalgoo Arezoo, Kheirandish Masoumeh, Porteghali Parham, Heidarzad Forough, Zeinali Taraneh, Ghanaei Fariborz Mansour, Hassanipour Soheil, Ulrich Michael T, Melson Joshua E, Patel Dhruvan, Nayak Sandeep Samethadka
Аннотация
METHODS: PubMed, Scopus and Web of Science databases were systematically searched up to May 2023. Heterogeneity was assessed using Cochran's Q test and I2 statistics, and random-effects model was used for meta-analysis. Analyses were performed using STATA version 18.
RESULTS: A total of 479 studies with 78,001,755 participants from 38 countries were finally included. The global prevalence of NAFLD was estimated to be 30.2% (95% CI: 28.7-31.7%). Regionally, the prevalence of NAFLD was as follows: Asia 30.9% (95% CI: 29.2-32.6%), Australia 16.1% (95% CI: 9.0-24.8%), Europe 30.2% (95% CI: 25.6-35.0%), North America 29% (95% CI: 25.8-32.3%), and South America 34% (95% CI: 16.9-53.5%). Countries with a higher human development index (HDI) had significantly lower prevalence of NAFLD (coefficient = -0.523, p = 0.005). Globally, the prevalence of NAFLD in men and women was 36.6% (95% CI: 34.7-38.4%) and 25.5% (95% CI: 23.9-27.1%), respectively. The prevalence of NAFLD in adults, adults with obesity, children, and children with obesity was 30.2% (95% CI: 28.8-31.7%), 57.5% (95% CI: 43.6-70.9%), 14.3% (95% CI: 10.3-18.8%), and 38.0% (95% CI: 31.5-44.7%), respectively.
CONCLUSION: The prevalence of NAFLD is remarkably high, particularly in countries with lower HDI. This substantial prevalence in both adults and children underscores the need for disease management protocols to reduce the burden.